Johnson & Johnson announced on May 5, 2026 the results of the first clinical study of its investigational OTTAVA Robotic Surgical System, a soft-tissue surgical robot the company has spent nearly a decade developing. In a prospective, multicenter study of 30 patients undergoing Roux-en-Y gastric bypass, every procedure was completed robotically on OTTAVA without a single conversion to a non-robotic, open approach. The trial met its primary safety and performance endpoints through 30 days post-procedure, and patients had lost an average of 30 pounds by that point.
A Decade-Long Bet on Soft-Tissue Robotics
OTTAVA has been one of the most closely watched programs in surgical robotics because it targets general and bariatric surgery rather than the urology and gynecology procedures that have long dominated robotic-assisted surgery through Intuitive Surgical’s da Vinci system. J&J built OTTAVA around integrated imaging, a compact footprint designed to fit existing operating rooms, and software intended to help surgeons plan and adjust instrument movement in real time. The gastric bypass trial marks the system’s first reported use in live patients after years of preclinical and bench testing.
What the Data Actually Show
The 30-patient cohort is small by the standards of pivotal device trials, and J&J has been careful to frame the results as safety and performance validation rather than proof of superiority over existing robotic or laparoscopic techniques. Investigators tracked complication rates, operative times and conversion rates, and the headline finding, that no case required conversion to open surgery, is notable because conversions are often used as a proxy for how well a robotic platform handles unexpected anatomy or complications mid-procedure.
Why Bariatric Surgery Was the Test Case
Gastric bypass was chosen partly because it is a high-volume procedure with well-established outcome benchmarks, including weight loss trajectories, making it easier to compare OTTAVA’s performance against decades of laparoscopic and robotic bariatric surgery data. The 30-pound average weight loss at 30 days is consistent with expected early outcomes for Roux-en-Y bypass generally, suggesting the robotic platform did not compromise the metabolic effectiveness of the procedure.
The Competitive and Regulatory Backdrop
OTTAVA enters a robotic surgery market that has grown more crowded. Medtronic’s Hugo RAS system received FDA clearance in December 2025 for urologic procedures after its Expand URO trial, and legacy player Intuitive Surgical continues to expand indications for da Vinci. Analysts and surgeons who have not worked with OTTAVA caution that a 30-patient safety study, while encouraging, is a long way from the multi-thousand-case real-world experience that has built confidence in da Vinci over two decades. Complication rates that look strong in a curated academic trial with experienced surgeons do not always hold up once a device is distributed to community hospitals with less specialized training.
What’s Next
J&J has not yet said when it will seek FDA clearance for OTTAVA or in which procedure categories it will first file. The company is expected to expand testing to additional soft-tissue procedures beyond bariatric surgery, and hospital systems will be watching whether OTTAVA’s pricing and integration costs make it a realistic alternative to established robotic platforms. For patients, the more immediate question is whether larger trials replicate the zero-conversion result across more complex cases and less experienced surgical teams, a test the 30-patient study by design could not answer.
